Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: Systematic review and meta-analysis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Chuang, Yu Chung ^a,b   Wang, Jann Tay ^a   Lin, Hsin Yi ^c   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

Daptomycin; Linezolid; Meta analysis; Vancomycin resistant enterococci

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTICLE; BACTERICIDAL ACTIVITY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; ENTEROCOCCAL INFECTION; HUMAN; HYPERTRANSAMINASEMIA; META ANALYSIS; MORTALITY; RECURRENCE RISK; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCAL BACTEREMIA; ANTIBIOTIC RESISTANCE; BACTEREMIA; COMPARATIVE STUDY; DRUG EFFECTS; MICROBIOLOGY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; HUMANS; LINEZOLID; OXAZOLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84924036447     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0687-9     Document Type: Article

References (41)

1. Leclercq R, Derlot E, Duval J, Courvalin P: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988, 319:157-161.
2. Uttley AH, Collins CH, Naidoo J, George RC: Vancomycin-resistant enterococci. Lancet 1988, 1:57-58.
3. Murray BE: Vancomycin-resistant enterococcal infections. N Engl J Med 2000, 342:710-721.
4. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA: Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005, 41:327-333.
5. Arias CA, Contreras GA, Murray BE: Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010, 16:555-562.
6. Moellering RC: Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003, 138:135-142.
7. Cattoir V, Leclercq R: Twenty-five years of shared life with vancomycin-resistant enterococci: Is it time to divorce. J Antimicrob Chemother 2013, 68:731-742.
8. Rybak MJ, Hershberger E, Moldovan T, Grucz RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother 2000, 44:1062-1066.
9. Kvirikadze N, Suseno M, Vescio T, Kaminer L, Singh K: Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 2006, 38:290-292.
10. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR: Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007, 54:567-571.
11. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C: Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009, 29:792-799.
12. Mave V, Garcia-Diaz J, Islam T, Hasbun R: Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009, 64:175-180.
13. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J: Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther 2010, 32:1713-1719.
14. Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD: Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer 2011, 19:1969-1974.
15. Bio LL, Perez ME, MacDougall C, Gallagher JC: Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia. Infect Dis Clin Pract 2011, 19:343-347.
16. McKinnell JA, Patel M, Shirley RM, Kunz DF, Moser SA, Baddley JW: Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect 2011, 139:1342-1350.
17. Chou CH, Lee NY, Lee HC, Chang CM, Lee CC, Ko WC: Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan. J Microbiol Immunol Infect 2012, 45:221-227.
18. Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, Broyles JE: Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med 2012, 7:243-248.
19. Barbour S, Marion C, Kennedy L, Russell GB, High K: Treatment of vancomycin-resistant enterococcal bacteremia in an observational cohort of neutropenic oncology patients daptomycin versus linezolid. Infect Dis Clin Pract 2013, 21:240-246.
20. Erlandson KM, Sun J, Iwen PC, Rupp ME: Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008, 46:30-36.
21. Whang DW, Miller LG, Partain NM, McKinnell JA: Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013, 57:5013-5018.
22. Balli EP, Venetis CA, Miyakis S: Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014, 58:734-739.
23. Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME: From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005, 19:673-680.
24. Lu CL, Chuang YC, Chang HC, Chen YC, Wang JT, Chang SC: Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis. J Antimicrob Chemother 2012, 67:2243-2249.
25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
26. Linden PK: Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007, 28:632-645.
27. Wang JL, Hsueh PR: Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009, 10:785-796.
28. Shukla BS, Gauthier TP, Correa R, Smith L, Abbo L: Treatment considerations in vancomycin-resistant enterococcal bacteremia: Daptomycin or linezolid? A review. Int J Clin Pharmacol 2013, 35:697-703.
29. Harbour R, Miller J: A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336.
30. Furuya EY, Kubin C, Yin M, Lowy F, Della-Latta P, Hammer S: Daptomycin Experience And Comparison With Linezolid For The Treatment Of Vancomycin-Resistant Enterococcal Bacteremia. In 45th Intersci Conf Antimicrob Agents Chemother; 2005. abstr K-2116.
31. El-Lababidi RM, Topal J, Tsukerman M: Daptomycin And Linezolid In The Treatment Of Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Analysis Of Treatment Outcomes. In 45th Annu Meet Infect Dis Soc Am; 2007. abstr 1095.
32. Dubrovskaya Y, Kubin CJ, Furuya EY: Daptomycin (D) Compared To Linezolid (L) For Primary Treatment Of Vancomycin-Resistant Enterococcal Bacteremia (VREB). In 46th Annu Meet Infect Dis Soc Am; 2008. abstr K-3443.
33. Marion C, Kennedy L, High K: Daptomycin Or Linezolid In The Treatment Of Vancomycin-Resistant Enterococcal Bacteremia In Neutropenic Cancer Patients. In 46th Annu Meet Infect Dis Soc Am; 2008. abstr L-2120.
34. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G: Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007, 13:615-621.
35. Pankey GA, Sabath LD: Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004, 38:864-870.
36. Tally FP, DeBruin MF: Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000, 46:523-526.
37. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
38. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001, 135:484-492.
39. Stafford KA, Boutin M, Evans SR, Harris AD: Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies. Clin Infect Dis 2014, 59:1142-1147.
40. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J: Worldwide assessment of linezolid's clinical safety and tolerability: Comparator-controlled phase III studies. Antimicrob Agents Chemother 2003, 47:1824-1831.
41. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ: Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002, 46:2723-2726.